AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does ABCELLERA BIOLOGICS (8QQ) operate in?
ABCELLERA BIOLOGICS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is ABCELLERA BIOLOGICS (8QQ) current stock price?
As of the latest data, ABCELLERA BIOLOGICS stock price is €11.28, with a previous close of €10.98. ABCELLERA BIOLOGICS gained €0.30 in the last trading session, representing a 2.73% increase.
What is ABCELLERA BIOLOGICS (8QQ) current market capitalization?
ABCELLERA BIOLOGICS market cap is approximately 3.66 billion.
What is ABCELLERA BIOLOGICS (8QQ) Earnings Per Share (EPS)?
The trailing EPS is -€0.46.
What is ABCELLERA BIOLOGICS (8QQ) EBITDA?
ABCELLERA BIOLOGICS EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -43.90 million.
Does ABCELLERA BIOLOGICS (8QQ) pay dividends?
No. ABCELLERA BIOLOGICS does not pay a dividend.
When is ABCELLERA BIOLOGICS (8QQ) next earnings report?
ABCELLERA BIOLOGICS is expected to release its next earnings report on September 30, 2026.
What is ABCELLERA BIOLOGICS (8QQ) beta (volatility) score?
ABCELLERA BIOLOGICS has a beta of 1.410, suggesting it is more volatile than the market.
